Related Experiment Video
Updated: Sep 9, 2025
06:26
Nano-Differential Scanning Fluorimetry for Screening in Fragment-based Lead Discovery
Published on: May 16, 2021
5.0K
Multiscale Computational and Pharmacophore-Based Screening of ALK Inhibitors with Experimental Validation
Ya-Kun Zhang1, Jian-Bo Tong1, Yue Sun1
1College of Chemistry and Chemical Engineering, Shaanxi University of Science and Technology, Xi'an 710021, China.
Pharmaceuticals (Basel, Switzerland)
|August 28, 2025
Summary
Researchers identified new Anaplastic Lymphoma Kinase (ALK) inhibitor candidates to combat cancer drug resistance. Computational and experimental methods revealed promising compounds for further development in targeted cancer therapy.
Area of Science:
- Oncology
- Medicinal Chemistry
- Computational Biology
Background:
- Anaplastic Lymphoma Kinase (ALK) is crucial for cell growth; its dysregulation drives cancer.
- Current ALK inhibitors offer benefits but face challenges with drug resistance.
- Novel ALK inhibitors are needed to overcome resistance and improve long-term cancer treatment efficacy.
Purpose of the Study:
- To discover novel Anaplastic Lymphoma Kinase (ALK) inhibitors.
- To overcome existing drug resistance mechanisms in ALK-driven cancers.
- To provide a rational design strategy for optimized ALK inhibitors.
Main Methods:
- Constructed a structure-based pharmacophore model using existing ALK inhibitors.
- Performed virtual screening of a drug-like database with PAINS filtering, ADMET prediction, and molecular docking.
- Evaluated antiproliferative activity, binding modes, and mechanisms using in vitro assays, molecular dynamics, and binding free energy calculations.
Main Results:
- Identified two potential ALK inhibitor candidates: F1739-0081 and F2571-0016.
- F1739-0081 demonstrated moderate antiproliferative effects against the A549 cell line.
- Computational analyses elucidated the binding interactions of F1739-0081 with ALK, supporting its activity.
Conclusions:
- Successfully identified novel ALK inhibitor candidates with potential therapeutic value.
- The integrated computational and experimental approach facilitates rational drug design.
- Findings offer insights for developing next-generation ALK inhibitors to address cancer drug resistance.
